Beovu
| Chemical Name | brolucizumab–dbll |
| Dosage Form | Injectable (intravitreal; 6 mg/0.05 mL) |
| Drug Class | Monoclonal antibodies |
| System | Ocular |
| Company | Novartis |
| Approval Year | 2019 |
Indication
- Beovu is indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD).